Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18–25 kinase domain duplication: report of two cases-Reference-Cited by-同舟云学术

Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18–25 kinase domain duplication: report of two cases

Published:2021-07-12 Issue:1 Volume:33 Page:e486-e490
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Zhang Long-Dan,Gao Han,Qin Shou-Ming,Zeng Qian,Chen Quan-Fang

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference11 articles.

1. Structure-function analysis of oncogenic EGFR kinase domain duplication reveals insights into activation and a potential approach for therapeutic targeting.;Du;Nat Commun,2021

2. A novel oncogenic driver in a lung adenocarcinoma patient harboring an EGFR-KDD and response to afatinib.;Chen;Front Oncol,2020

3. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.;Costa;Transl Lung Cancer Res,2016

4. Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication.;Baik;J Thorac Oncol,2015

5. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.;Wang;Int J Cancer,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review;Frontiers in Oncology;2024-06-21

2. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors;The Oncologist;2024-05-31

3. Receptor tyrosine kinase inhibitors in cancer;Cellular and Molecular Life Sciences;2023-03-22

4. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer;Biomolecules;2023-01-20

5. Multiple drugs;Reactions Weekly;2022-12-03